Nasopharyngeal Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

NPC MCID: NSP012 MIFTS: 62	Nasopharyngeal Carcinoma (NPC) Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Oral diseases, Rare diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Nasopharyngeal Carcinoma

MalaCards integrated aliases for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma ⁵⁷ ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ²⁸ ⁵³ ⁵ ¹⁴ ³⁸ ⁷¹

Malignant Neoplasm of Nasopharynx ¹¹ ⁷¹ ³¹

Nasopharyngeal Carcinoma 1 ⁵⁷ ¹²

Nasopharyngeal Neoplasms ⁴³ ⁷¹

Nasopharyngeal Cancer ⁵⁷ ¹⁹

Nasopharynx Carcinoma ¹¹ ¹⁴

Npc ⁵⁷ ¹⁶

Squamous Cell Carcinoma of the Nasopharynx ⁵⁸

Malignant Nasopharyngeal Tumor ¹¹

Carcinoma of Nasopharynx ¹¹

Nasopharyngeal Neoplasm ¹⁶

Cancer of Nasopharynx ⁷¹

Nasopharynx Cancer ¹¹

Npca ⁵⁷

Characteristics:

Inheritance:

Multigenic/multifactorial ⁵⁸

Prevelance:

1-9/1000000 (China, Europe, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-9/100000 (Europe, Malta) ⁵⁸

Age Of Onset:

All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Respiratory diseases Gastrointestinal diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms of lip, oral cavity and pharynx

Malignant neoplasm of nasopharynx

Malignant neoplasm: Anterior wall of nasopharynx

Malignant neoplasm: Lateral wall of nasopharynx

Malignant neoplasm: Nasopharynx, unspecified

Malignant neoplasm: Posterior wall of nasopharynx

Malignant neoplasm: Superior wall of nasopharynx

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of lip, oral cavity or pharynx

Malignant neoplasms of nasopharynx

Squamous cell carcinoma of nasopharynx

Orphanet: ⁵⁸

Rare respiratory diseases

External Ids:

Disease Ontology ¹¹ DOID:9261

OMIM® ⁵⁷ 607107

ICD9CM ³⁴ 147 147.0 147.1 more

MeSH ⁴³ D009303

NCIt ⁴⁹ C9321

SNOMED-CT ⁶⁸ 187692001 187693006 187700006 more

ICD10 ³¹ C11 C11.0 C11.1 more

MESH via Orphanet ⁴⁴ C538339

ICD10 via Orphanet ³² C11.0 C11.1 C11.2 more

UMLS via Orphanet ⁷² C0153392 C0238301 C2931822

Orphanet ⁵⁸ ORPHA150

MedGen ⁴⁰ C2931822

SNOMED-CT via HPO ⁶⁹ 126680004

EFO ¹⁶ EFO_0004041 EFO_0004252

ICD11 ³³ 294167983

UMLS ⁷¹ C0027439 C0153392 C0153393 more

Sources

Summaries for Nasopharyngeal Carcinoma

OMIM®: ⁵⁷ Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx. The Epstein-Barr virus has been implicated (Tse et al., 2009). (607107) (Updated 08-Dec-2022)

MalaCards based summary: Nasopharyngeal Carcinoma, also known as malignant neoplasm of nasopharynx, is related to squamous cell carcinoma and burkitt lymphoma, and has symptoms including headache, tinnitus and rhinorrhea. An important gene associated with Nasopharyngeal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are miRNAs involved in DNA damage response and let-7 inhibition of ES cell reprogramming. The drugs Fentanyl and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, t cells and skin, and related phenotype is neoplasia of the nasopharynx.

Disease Ontology: ¹¹ A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or throat, where the nasal passages and auditory tubes join the remainder of the upper respiratory tract.

GARD: ¹⁹ Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial cells that cover the surface and line the nasopharynx.

Orphanet: ⁵⁸ Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial cells that cover the surface and line the nasopharynx.

Wikipedia: ⁷⁵ Nasopharyngeal carcinoma (NPC), or nasopharynx cancer, is the most common cancer originating in the... more...

Sources

Related Diseases for Nasopharyngeal Carcinoma

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 2

Nasopharyngeal Carcinoma 3

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 860)

#	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma	31.8	TP53 NEAT1 MALAT1 HOTAIR H19 FOXCUT
2	burkitt lymphoma	31.8	TP53 PVT1 NFKBIA NEAT1
3	squamous cell carcinoma, head and neck	31.7	TP53 NFKBIA MIR29C HOTAIR H19
4	b-cell lymphoma	31.6	TP53 PVT1 NFKBIA MALAT1 HOTAIR
5	osteogenic sarcoma	31.4	XIST TP53 PVT1 NEAT1 MEG3 MALAT1
6	gastric cancer	31.4	XIST TP53 PVT1 NPTN-IT1 NFKBIA NEAT1
7	esophageal cancer	31.2	TP53 PVT1 MIR100 MEG3 MALAT1 HOTAIR
8	thyroid carcinoma	31.1	PVT1 NEAT1 MALAT1 LINC00312 HOTAIR H19
9	breast cancer	31.0	XIST TP53 PVT1 NFKBIA NEAT1 MIR29C
10	lung cancer susceptibility 3	31.0	TP53 NPTN-IT1 MEG3 MALAT1 LINC-ROR HOTAIR
11	cervical cancer	30.9	TP53 PVT1 NPTN-IT1 NEAT1 MEG3 MALAT1
12	hepatocellular carcinoma	30.9	XIST TP53 PVT1 NPTN-IT1 NFKBIA NEAT1
13	retinitis pigmentosa 11	30.9	XIST TP53 PVT1 NEAT1 HOTAIR CDKN2B-AS1
14	myeloma, multiple	30.8	TP53 PVT1 NFKBIA MEG3 MALAT1 HOTAIR
15	lung cancer	30.8	XIST TP53 PVT1 PCAT7 NFKBIA NEAT1
16	small cell cancer of the lung	30.7	TP53 MALAT1 HOTAIR
17	laryngeal squamous cell carcinoma	30.7	TP53 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
18	tongue carcinoma	30.7	TP53 MIR100 MALAT1
19	colorectal cancer	30.6	XIST TP53 PVT1 NPTN-IT1 NFKBIA NEAT1
20	pituitary adenoma	30.6	MEG3 MALAT1 HOTAIR H19
21	neuroblastoma	30.6	TP53 MIR29C MEG3 MALAT1 HOTAIR H19
22	esophagus squamous cell carcinoma	30.6	XIST PVT1 NPTN-IT1 MEG3 MALAT1 LINC00460
23	bladder cancer	30.5	XIST TP53 PVT1 MIR29C MIR100 MEG3
24	glioblastoma	30.5	XIST TP53 MEG3 MALAT1 HOTAIR H19
25	renal cell carcinoma, nonpapillary	30.5	TP53 PVT1 NPTN-IT1 MIR29C MIR100 MEG3
26	ovarian cancer	30.5	XIST TP53 PVT1 NFKBIA NEAT1 MIR29C
27	glioma	30.5	TP53 PVT1 NEAT1 MEG3 MALAT1 HOTAIR
28	oral squamous cell carcinoma	30.5	NEAT1 MIR100 MEG3 MALAT1 HOTAIR H19
29	pancreatic cancer	30.5	XIST TP53 PVT1 NFKBIA NEAT1 MIR100
30	melanoma	30.5	XIST TP53 PVT1 MIR100 MEG3 MALAT1
31	tongue squamous cell carcinoma	30.5	TP53 MEG3 MALAT1 AFAP1-AS1
32	high grade glioma	30.4	XIST TP53 PVT1 NEAT1 MEG3 MALAT1
33	thyroid cancer, nonmedullary, 1	30.4	TP53 PVT1 NEAT1 MEG3 MALAT1 LINC-ROR
34	leukemia, chronic myeloid	30.4	TP53 NFKBIA MEG3 HOTAIR H19
35	lung squamous cell carcinoma	30.3	TP53 PVT1 NPTN-IT1 MEG3
36	prostate cancer	30.2	XIST TP53 PVT1 PCAT7 NFKBIA NEAT1
37	leukemia, acute myeloid	30.2	TP53 MEG3 MALAT1 HOTAIR CDKN2B-AS1
38	nasopharyngeal carcinoma 3	11.7
39	nasopharyngeal carcinoma 2	11.7
40	lymphoepithelioma-like carcinoma	11.1
41	mucositis	11.0
42	head and neck cancer	10.9
43	aplasia of lacrimal and salivary glands	10.9
44	neutropenia	10.8
45	nasopharyngitis	10.8
46	factor vii deficiency	10.7
47	otitis media	10.7
48	osteonecrosis	10.7
49	rhabdomyosarcoma 2	10.7
50	viral infectious disease	10.7

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):

Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:

Sources

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

Human phenotypes related to Nasopharyngeal Carcinoma:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	neoplasia of the nasopharynx ³⁰			HP:0100630

Clinical features from OMIM®:

607107 (Updated 08-Dec-2022)

UMLS symptoms related to Nasopharyngeal Carcinoma:

headache; tinnitus; rhinorrhea

Sources

Drugs & Therapeutics for Nasopharyngeal Carcinoma

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 299)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Erythromycin

Approved, Investigational, Vet_approved

Phase 4

114-07-8

12560

Azithromycin

Approved

Phase 4

83905-01-5

447043

Cisplatin

Approved

Phase 4

15663-27-1

2767 5702198 441203

Docetaxel

Approved, Investigational

Phase 4

114977-28-5

148124

Rofecoxib

Approved, Investigational, Withdrawn

Phase 4

162011-90-7

5090

Anti-Bacterial Agents

Phase 4

Analgesics, Opioid

Phase 4

Narcotics

Phase 4

Gastrointestinal Agents

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, General

Phase 4

Erythromycin stearate

Phase 4

Erythromycin Ethylsuccinate

Phase 4

Erythromycin Estolate

Phase 4

Antimitotic Agents

Phase 4

Tubulin Modulators

Phase 4

Cyclooxygenase 2 Inhibitors

Phase 4

Fluorouracil

Approved

Phase 3

51-21-8

3385

Tegafur

Approved, Investigational

Phase 3

17902-23-7

5386

Acyclovir

Approved

Phase 3

59277-89-3

2022

Oprelvekin

Approved, Investigational

Phase 3

145941-26-0

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Epirubicin

Approved

Phase 3

56420-45-2

41867

Mitomycin

Approved

Phase 3

50-07-7

5746

Ursodeoxycholic acid

Approved, Investigational

Phase 2, Phase 3

128-13-2

31401

Fluticasone

Approved, Experimental

Phase 3

90566-53-3

4659387 5311101

Benralizumab

Approved, Investigational

Phase 3

1044511-01-4

Atezolizumab

Approved, Investigational

Phase 2, Phase 3

1380723-44-3

Tropisetron

Approved, Investigational

Phase 3

105826-92-4, 89565-68-4

656665

Paclitaxel

Approved, Vet_approved

Phase 2, Phase 3

33069-62-4

36314

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Capecitabine

Approved, Investigational

Phase 3

154361-50-9

60953

Nedaplatin

Approved, Investigational

Phase 3

95734-82-0

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

4112 126941

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Etoposide

Approved

Phase 3

33419-42-0

36462

Celecoxib

Approved, Investigational

Phase 3

169590-42-5

2662

Mometasone furoate

Approved, Investigational, Vet_approved

Phase 3

83919-23-7

4240 441336

Budesonide

Approved

Phase 3

51333-22-3

5281004 40000 63006

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Nimotuzumab

Investigational

Phase 3

780758-10-3

Palifosfamide

Investigational

Phase 3

31645-39-3

100427

Endostatins

Phase 3

Interventional clinical trials:

(show top 50) (show all 699)

#	Name	Status	NCT ID	Phase	Drugs
1	Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma	Unknown status	NCT02293356	Phase 4	Nimotuzumab Injection
2	Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury After Therapy With Docetaxel and Cisplatin for Nasopharyngeal Carcinoma	Unknown status	NCT03069820	Phase 4	docetaxel and cisplatin
3	A Prospective, Randomized Controlled Open Research About the Impact of Nutritional Support on the Radiation Tolerance and Clinical Outcomes for Local Advanced Nasopharyngeal Carcinoma Patients	Unknown status	NCT02948699	Phase 4
4	A Comparison of Oral Controlled-release Morphine With Transdermal Fentanyl in Nasopharyngeal Cancer Patients With Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy	Unknown status	NCT04292990	Phase 4	Fentanyl;Morphine
5	Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version	Unknown status	NCT02354560	Phase 4	Erythromycin
6	Azithromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis	Unknown status	NCT04454151	Phase 4	Azithromycin Tablets
7	Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough.	Unknown status	NCT02175914	Phase 4	Erythromycin
8	Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors	Completed	NCT01344356	Phase 4
9	Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx	Completed	NCT00772681	Phase 4	docetaxel and cisplatin
10	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP)	Terminated	NCT00140894	Phase 4	MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
11	A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage Ⅲ Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma	Unknown status	NCT01915134	Phase 3	Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
12	Induction Chemotherapy of Docetaxel, Cisplatin and Xeloda in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT02786641	Phase 3	Docetaxel;Cisplatin 1;Xeloda;Cisplatin 2
13	Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era	Unknown status	NCT02633202	Phase 3	Cisplatin
14	Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy With or Without Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT01872962	Phase 3	gemcitabine and cisplatin (Induction chemotherapy)
15	Intensity Modulated Radiotherapy Plus Cisplatin Versus Intensity Modulated Radiotherapy in Patients With Stage 2 Nasopharyngeal Carcinoma: A Phase 3 Multicenter, Open-label, Randomized, Non-inferior Clinical Trial	Unknown status	NCT03068936	Phase 3	Cisplatin
16	A Multicenter Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT00677118	Phase 3	Cisplatin,fluorouracil;Cisplatin
17	Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated Radiotherapy With or Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT01854203	Phase 2, Phase 3	Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
18	Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT01689558	Phase 2, Phase 3	Recombine Endostatin
19	Multicentre Randomization Clinic Trial of Systemic Chemotherapy Combined With Loco-regional Radiotherapy vs. Chemotherapy Alone for Initially Untreated Distant Metastatic Nasopharyngeal Carcinoma With Chemosensitivity	Unknown status	NCT02111460	Phase 3
20	Fine Needle Aspiration of Retropharyngeal Lymph Node Guided by Endoscopic Ultrasound for the Diagnosis of Patients With Suspected Recurrent Nasopharyngeal Carcinoma	Unknown status	NCT03006588	Phase 2, Phase 3
21	A Multicenter Trial Comparing Neoadjuvant Chemotherapy Followed by CCRT v.s. CCRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT00705627	Phase 3	neoadjuvant chemotherapy plus concurrent chemoradiotherapy
22	A Single Center, Open-label, Randomized Controlled Clinical Trial on the Early and Whole Course Nutritional Support by Nutren® Optimum During Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma	Unknown status	NCT03344068	Phase 2, Phase 3	Chemotherapy
23	A Randomized Phase III Non-inferiority Study of Induction Chemotherapy Followed by IMRT Alone Versus Induction Chemotherapy Followed by IMRT Plus Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT02434614	Phase 3	Docetaxel,Cisplatin,Fluorouracil;Cisplatin
24	Randomized Phase III Study in EBV Positive Locally Advanced Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug	Unknown status	NCT03656965	Phase 3	Acyclovir 800 MG
25	Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma	Unknown status	NCT03601975	Phase 3	Gemcitabine/Cisplatin
26	Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma	Unknown status	NCT02500940	Phase 3	Cisplatin;Fluorouracil;Leucovorin
27	A Phase III Randomized Trial of Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage	Unknown status	NCT03403829	Phase 3	Gemcitabine
28	A Multicenter, Randomized Controlled Phase III Clinical Trial of GP Induction Chemotherapy With TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT03604965	Phase 3	GP+CCRT;TPF+CCRT
29	The Effect of Celecoxib on Concurrent Chemoradiation With Weekly Nedaplatin in Nasopharyngeal Carcinoma	Unknown status	NCT02537925	Phase 3	Celecoxib;Nedaplatin
30	Phase III Randomized Trial of Immediate Adjuvant Chemotherapy or Delayed Salvage Chemotherapy in Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA	Unknown status	NCT02363400	Phase 3	MEP
31	Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT01245959	Phase 3	Docetaxel, cisplatin and fluorouracil
32	Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Following High-dose Cisplatin in Nasopharyngeal Carcinoma Patients：a Randomized Phase 3 Trial	Unknown status	NCT02933099	Phase 3	Aprepitant+palonosetron+dexamethasone;palonosetron+dexamethasone
33	A Randomized Phase III Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma	Unknown status	NCT02944708	Phase 3	Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
34	A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)	Unknown status	NCT02907710	Phase 3	Endostar;DDP
35	A Multicenter Trial Evaluating the Efficacy and Safety of Nedaplatin Plus Docetaxel in Neoadjuvant Chemotherapy Followed by Nedaplatin in Concurrent Chemoradiation for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT01479504	Phase 3	nedaplatin and docetaxel;cisplatin and docetaxel
36	Cisplatin and 5-fluorouracil(PF) or Docetaxel,Cisplatin and 5-fluorouracil (TPF) Neoadjuvant Chemotherapy With Chemoradiation Therapy for Locally Advanced Nasopharyngeal Carcinoma--A Randomised Prospective Multicenter Phase 3 Study	Unknown status	NCT01536223	Phase 3	PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
37	Multicenter Phase III Study of Intensity-modulated Radiotherapy Alone Compared to Intensity-modulated Radiotherapy Combined Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma	Unknown status	NCT01817023	Phase 3	Cisplatin
38	A Randomized Phase III Study of Concurrent Weekly Nedaplatin or Cisplatin With IMRT in NPC Patients	Unknown status	NCT02301208	Phase 3	Nedaplatin;Cisplatin
39	The Open and Multi-center Phase III Clinical Study of Interleukin-11 in the Prevention and Treatment of Radioactive Oral Mucitis	Unknown status	NCT03720340	Phase 3	Recombinant Human Interleukin-11;Saline
40	MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.	Unknown status	NCT00180973	Phase 3	Hydroxyurea
41	A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer	Unknown status	NCT01074021	Phase 3	Nimotuzumab;placebo plus chemoradiotherapy
42	Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF	Unknown status	NCT00134758	Phase 2, Phase 3	Ursodeoxycholic acid;Placebo
43	Standard Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Adjuvant Chemotherapy for Locally Advanced (Non-Metastatic) Nasopharyngeal Cancer	Unknown status	NCT00003637	Phase 3	cisplatin;fluorouracil
44	Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma	Completed	NCT00379262	Phase 3	Capecitabine;Adjuvant chemotherapy using PF (5-Fluorouracil );Induction chemotherapy using PF (5-Fluorouracil)
45	Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial	Completed	NCT02143388	Phase 3	IMRT combine with cisplatin concurrent chemotherapy;IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
46	A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients	Completed	NCT02578641	Phase 3	combination IV gemcitabine and IV carboplatin (AUC2)
47	Late-Course Accelerated Hyperfractionated IMRT Versus Conventionally Fractionated IMRT in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Clinical Trial	Completed	NCT00778908	Phase 2, Phase 3	Concomitant cisplatin chemotherapy
48	Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy With Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).	Completed	NCT02012062	Phase 3	TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy
49	The Multicenter Randomized Phase 3 Trial of Individualized Elective Neck Irradiation Based on MRI in Patients With Nasopharyngeal Carcinoma	Completed	NCT02642107	Phase 3
50	A Multicenter Phase III Trial Comparing Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Stage IV Nasopharyngeal Carcinoma (NPC)	Completed	NCT00201396	Phase 3	Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Sources

Genetic Tests for Nasopharyngeal Carcinoma

Genetic tests related to Nasopharyngeal Carcinoma:

#	Genetic test	Affiliating Genes
1	Nasopharyngeal Carcinoma ²⁸	TP53

Sources

Anatomical Context for Nasopharyngeal Carcinoma

Organs/tissues related to Nasopharyngeal Carcinoma:

MalaCards : Lymph Node, T Cells, Skin, Temporal Lobe, Salivary Gland, Nk Cells, Liver

Sources

Publications for Nasopharyngeal Carcinoma

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 16913)

#	Title	Authors	PMID	Year
1	An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. ⁶² ⁵⁷ ⁵	Sun Y...Colburn NH	1631151	1992
2	The genomic landscape of nasopharyngeal carcinoma. ⁶² ⁵⁷	Lin DC...Koeffler HP	24952746	2014
3	A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. ⁶² ⁵⁷	Bei JX...Zeng YX	20512145	2010
4	Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. ⁶² ⁵⁷	Tse KP...Shugart YY	19664746	2009
5	A functional variant in the transcriptional regulatory region of gene LOC344967 cosegregates with disease phenotype in familial nasopharyngeal carcinoma. ⁶² ⁵⁷	Jiang RC...Zeng YX	16423998	2006
6	Association of PLUNC gene polymorphisms with susceptibility to nasopharyngeal carcinoma in a Chinese population. ⁶² ⁵⁷	He Y...Yao K	15689457	2005
7	A rare polymorphism of the COX7B2 gene in a Cantonese family with nasopharyngeal carcinoma. ⁶² ⁵⁷	Liang H...Zeng Y	15623157	2004
8	Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. ⁶² ⁵⁷	Feng BJ...Zeng YX	12118254	2002
9	Familial nasopharyngeal carcinoma. ⁶² ⁵⁷	Fischer A...Cooper E	6609336	1984
10	Familial clustering of nasopharyngeal carcinoma. ⁶² ⁵⁷	Gajwani BW...Beg JA	7191767	1980
11	Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. ⁶² ⁴⁶	Shi W...Liu FF	19739117	2010
12	Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from southeastern Asia. ⁵⁷	Chakrani F...May P	7729941	1995
13	Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. ⁵³ ⁶²	Wu CC...Yu JS	20124221	2010
14	[Tumor-targeted human telomerase reverse transcriptase promoter/tk gene therapy against human nasopharyngeal carcinoma cells in vitro]. ⁵³ ⁶²	Xu F...Guo MH	20423828	2010
15	Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. ⁵³ ⁶²	Jiang H...Deng H	20412566	2010
16	microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. ⁵³ ⁶²	Zhang L...Li G	20053927	2010
17	Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. ⁵³ ⁶²	Xiao M...Liu Y	20398418	2010
18	Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. ⁵³ ⁶²	Chen MK...Chen HC	20036222	2010
19	Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. ⁵³ ⁶²	Chen J...Shao JY	20338061	2010
20	Indole-3-carbinol inhibits nasopharyngeal carcinoma. ⁵³ ⁶²	Zhu W...Yang X	20335513	2010
21	[Study on the relationship between TK gene regulated by enhanced suicide gene vector and telomerase activity in nasopharyngeal carcinoma cells]. ⁵³ ⁶²	Shen C...Guan X	20422982	2010
22	Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells. ⁵³ ⁶²	Xu P...Lang JY	20109337	2010
23	Bax inhibitor-1 mediates apoptosis-resistance in human nasopharyngeal carcinoma cells. ⁵³ ⁶²	Zhang M...Zhou K	19579059	2010
24	Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. ⁵³ ⁶²	Law AY...Wong CK	19628018	2010
25	A case-control and a family-based association study revealing an association between CYP2E1 polymorphisms and nasopharyngeal carcinoma risk in Cantonese. ⁵³ ⁶²	Jia WH...Shugart YY	19805575	2009
26	Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. ⁵³ ⁶²	Koon HK...Mak NK	19816982	2009
27	Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. ⁵³ ⁶²	Wang T...Wu G	20042089	2009
28	PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. ⁵³ ⁶²	Fendri A...Mokdad-Gargouri R	19735264	2009
29	[Expression of HSP70/HSP27 protein in residual lesion after NPC radiotherapy]. ⁵³ ⁶²	Wang R...Feng X	19952398	2009
30	[Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression]. ⁵³ ⁶²	Cai YL...Zhong QY	20387494	2009
31	[Induced RAS association domain family gene 1A gene expression by arsenic trioxide in nasopharyngeal carcinoma cell]. ⁵³ ⁶²	Hu JL...Liang HH	20079060	2009
32	LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells. ⁵³ ⁶²	Liu H...Cao Y	19860880	2009
33	Role of p38 MAPKs in hypericin photodynamic therapy-induced apoptosis of nasopharyngeal carcinoma cells. ⁵³ ⁶²	Chan PS...Mak NK	19496992	2009
34	ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. ⁵³ ⁶²	Hu ZY...Zeng YX	19698176	2009
35	IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients. ⁵³ ⁶²	Ayadi W...Hammami A	19551836	2009
36	[The relationship between the expression of EGFR NF-kappaB and radiosensitivity in human nasopharyngeal carcinoma]. ⁵³ ⁶²	Yang C...Ai Y	19947250	2009
37	Regulation of RASSF1A in nasopharyngeal cells and its response to UV irradiation. ⁵³ ⁶²	Lee VH...Lee LT	19450668	2009
38	[Expression of E-cadherin and P(120ctn) in nasopharyngeal carcinoma and their relationship]. ⁵³ ⁶²	Ye H...Huang Z	19894558	2009
39	[Matrine enhances the cytotoxic sensitivity of ABCG2high nasopharyngeal carcinoma cells to natural killer cells by inducing high expression of NKG2D receptor ligands]. ⁵³ ⁶²	Huang YX...Guo KY	19620045	2009
40	[Association of nasopharyngeal carcinoma risk with cytochrome P450 CYP1A1 gene polymorphisms]. ⁵³ ⁶²	Xu YF...Jia WH	19954069	2009
41	Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. ⁵³ ⁶²	Niller HH...Minarovits J	19429479	2009
42	Curcuminoids suppress the growth of pharynx and nasopharyngeal carcinoma cells through induced apoptosis. ⁵³ ⁶²	Lin YT...Hsu YC	19317462	2009
43	Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma. ⁵³ ⁶²	Segawa Y...Tsuneyoshi M	19360294	2009
44	Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. ⁵³ ⁶²	Taheri-Kadkhoda Z...Bjork-Eriksson T	19132724	2009
45	[Association of CXCR4 and SDF-1alpha with organ-specific metastasis of nasopharyngeal carcinoma]. ⁵³ ⁶²	Luo HN...Liu YL	19615279	2009
46	Nasopharyngeal carcinoma in Brunei Darussalam: low incidence among the Chinese and an evaluation of antibodies to Epstein-Barr virus antigens as biomarkers. ⁵³ ⁶²	Yeo CH...Ramasamy R	19421680	2009
47	GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysis. ⁵³ ⁶²	Zhuo X...Zhang X	19338664	2009
48	Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. ⁵³ ⁶²	Fendri A...Mokdad-Gargouri R	19221469	2009
49	Dual silencing of epidermal growth factor and insulin-like growth factor 1 receptors significantly limits growth of nasopharyngeal carcinoma in nude mice. ⁵³ ⁶²	Zhou X...Xia D	18452630	2009
50	[Association of the T1270533G polymorphism in GSTM1 gene coding region with susceptibility to nasopharyngeal carcinoma in a Chinese population]. ⁵³ ⁶²	He Y...Yao KT	19218107	2009

Sources

Genes for Nasopharyngeal Carcinoma

Genes related to Nasopharyngeal Carcinoma (6 elite genes):

(show top 50) (show all 170)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TP53	Tumor Protein P53	Protein Coding	541.54	Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	1631151
2	MIR29C	MicroRNA 29c	RNA Gene	367.99	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18390668
3	NFKBIA	NFKB Inhibitor Alpha	Protein Coding	366.6	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	27647909 18007066
4	MIR100	MicroRNA 100	RNA Gene	358.23	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	19739117
5	NPCA2	Nasopharyngeal Carcinoma, Susceptibility To, 2	Genetic Locus	58.21	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
6	NPC1	NPC Intracellular Cholesterol Transporter 1	Protein Coding	53.05	Susceptibility factor ⁵⁷ DISEASES inferred ¹⁴
7	LINC00312	Long Intergenic Non-Protein Coding RNA 312	RNA Gene	182.69	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Summaries (show sections)	11780420 12452030 19591174 (more) 23529758
8	AFAP1-AS1	AFAP1 Antisense RNA 1	RNA Gene	164.67	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26246469
9	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	164.24	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	23281836 24817925
10	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	164.07	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	20512145 20956613 24817925 (more) 28402230
11	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	163.79	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	27020592 29050268
12	PVT1	Pvt1 Oncogene	RNA Gene	163.47	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	29445147
13	XIST	X Inactive Specific Transcript	RNA Gene	163.17	Experimental evidence: Locus ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	27461945
14	LINC00460	Long Intergenic Non-Protein Coding RNA 460	RNA Gene	162.91	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	28987345
15	NPTN-IT1	NPTN Intronic Transcript 1	RNA Gene	162.45	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26243049
16	FOXCUT	FOXC1 Upstream Transcript	RNA Gene	162.43	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	28635400
17	FOXD2-AS1	FOXD2 Adjacent Opposite Strand RNA 1	RNA Gene	162.37	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	29248577
18	LINC-ROR	Long Intergenic Non-Protein Coding RNA, Regulator Of Reprogramming	RNA Gene	162.34	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	27311700
19	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	162.07	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	23688988 24817925 26482776
20	PCAT7	Prostate Cancer Associated Transcript 7	RNA Gene	161.86	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	28728844
21	MEG3	Maternally Expressed 3	RNA Gene	161.38	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	27597634
22	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	160.62	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	27040767
23	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA	RNA Gene	157.17	Experimental evidence: Interaction ³⁷ GeneCards inferred via : Publications (show sections)	28445086
24	NKILA	NF-KappaB Interacting LncRNA	RNA Gene	157.17	Experimental evidence: Regulation ³⁷ GeneCards inferred via : Publications (show sections)	24379026
25	GAS5	Growth Arrest Specific 5	RNA Gene	155.64	Experimental evidence: Mutation ³⁷ DISEASES inferred ¹⁴	28977945
26	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	155.46	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	28358263
27	CASC9	Cancer Susceptibility 9	RNA Gene	155.28	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴	28398871
28	LINC01315	Long Intergenic Non-Protein Coding RNA 1315	RNA Gene	154.58	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	24822202
29	HNF1A-AS1	HNF1A Antisense RNA 1	RNA Gene	154.48	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26756620
30	AP5M1	Adaptor Related Protein Complex 5 Subunit Mu 1	Protein Coding	153.56	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24379026
31	LINC01544	Long Intergenic Non-Protein Coding RNA 1544	RNA Gene	150	Experimental evidence: Regulation ³⁷	24379026
32	LINC02577	Long Intergenic Non-Protein Coding RNA 2577	RNA Gene	150	Experimental evidence: Regulation ³⁷	27886062
33	lnc-ZNF674-1		RNA Gene	150	Experimental evidence: Expression ³⁷	24822202
34	MIR3936HG	MIR3936 Host Gene	RNA Gene	150	Experimental evidence: Regulation ³⁷	27584792
35	RPS24P1	Ribosomal Protein S24 Pseudogene 1	Pseudogene	150	Experimental evidence: Expression ³⁷	26448942
36	SMIM10L2A	Small Integral Membrane Protein 10 Like 2A	Protein Coding	150	Experimental evidence: Interaction ³⁷	28245169
37	MIR34C	MicroRNA 34c	RNA Gene	67.96	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18390668
38	MIR212	MicroRNA 212	RNA Gene	65.16	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18390668
39	MIR151A	MicroRNA 151a	RNA Gene	65.05	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18390668
40	MIR192	MicroRNA 192	RNA Gene	64.92	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18390668
41	MIR34B	MicroRNA 34b	RNA Gene	64.87	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18390668
42	MIR217	MicroRNA 217	RNA Gene	54.93	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18390668
43	MIR216A	MicroRNA 216a	RNA Gene	54.85	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18390668
44	TMEM8B	Transmembrane Protein 8B	Protein Coding	33.57	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Functions (show sections)
45	BPIFA1	BPI Fold Containing Family A Member 1	Protein Coding	32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Gene name (show sections)	12753706 16195890 16364440 (more) 20053927
46	UBAP1	Ubiquitin Associated Protein 1	Protein Coding	30.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Summaries (show sections)
47	CDH1	Cadherin 1	Protein Coding	22.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15571312 19894558 12751385 (more) 10425304 17007384 11568585 12760799 10208469 15229899 10996845 11801955 15361301
48	RASSF1	Ras Association Domain Family Member 1	Protein Coding	22.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20042089 12865217 11358799 (more) 17720308 15375500 19450668 19221469 20079060 16096369 16116475
49	BCL2	BCL2 Apoptosis Regulator	Protein Coding	22.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8732340 15514848 12788193 (more) 9158704 14676159 20036222 11263144 18442057 10743138 10797381 9744466 11787776 9635525 19698176 12838865 11979459 17020977 11053650 9367385 1817429 9783682 11783085 12893071
50	EGFR	Epidermal Growth Factor Receptor	Protein Coding	21.89	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12515612 18758376 19947250 (more) 13129707 11893453 19132724 16737616 18479591 17208308 12966511 16495180 17908353 16344724 19816982 15723947 15093894 10072985 7703798 11410322 8608524 18722874 18444479 15142450 18307254 15723283 17762933 17137327 16037687 17686610 18452630

Sources

Variations for Nasopharyngeal Carcinoma

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

⁵ (show all 11)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TP53	NM_000546.6(TP53):c.743G>A (p.Arg248Gln)	SNV	Pathogenic	12356	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
2	TP53	NM_000546.6(TP53):c.559+1G>A	SNV	Pathogenic	428908	rs1131691042	GRCh37: 17:7578370-7578370 GRCh38: 17:7675052-7675052
3	TP53	NM_000546.6(TP53):c.524G>A (p.Arg175His)	SNV	Pathogenic	12374	rs28934578	GRCh37: 17:7578406-7578406 GRCh38: 17:7675088-7675088
4	TP53	NM_000546.6(TP53):c.96+1G>T	SNV	Pathogenic	482212	rs1131691003	GRCh37: 17:7579699-7579699 GRCh38: 17:7676381-7676381
5	TP53	NM_000546.6(TP53):c.839G>C (p.Arg280Thr)	SNV	Pathogenic	12368	rs121912660	GRCh37: 17:7577099-7577099 GRCh38: 17:7673781-7673781
6	TP53	NM_000546.6(TP53):c.818G>A (p.Arg273His)	SNV	Pathogenic	12366	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
7	TP53	NM_000546.6(TP53):c.799C>T (p.Arg267Trp)	SNV	Likely Pathogenic	141764	rs55832599	GRCh37: 17:7577139-7577139 GRCh38: 17:7673821-7673821
8	TP53	NM_000546.6(TP53):c.466C>T (p.Arg156Cys)	SNV	Uncertain Significance	127810	rs563378859	GRCh37: 17:7578464-7578464 GRCh38: 17:7675146-7675146
9	TP53	NM_000546.6(TP53):c.461G>A (p.Gly154Asp)	SNV	Uncertain Significance	237950	rs762846821	GRCh37: 17:7578469-7578469 GRCh38: 17:7675151-7675151
10	TP53	NM_000546.6(TP53):c.847C>T (p.Arg283Cys)	SNV	Uncertain Significance	127824	rs149633775	GRCh37: 17:7577091-7577091 GRCh38: 17:7673773-7673773
11	TP53	NM_000546.6(TP53):c.760A>G (p.Ile254Val)	SNV	Uncertain Significance	406605	rs746601313	GRCh37: 17:7577521-7577521 GRCh38: 17:7674203-7674203

Cosmic variations for Nasopharyngeal Carcinoma:

⁸ (show top 50) (show all 195)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM143943797	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.266G>A	p.R89Q	17:7674220-7674220	13
2	COSM142560281	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	13
3	COSM144087106	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.266G>A	p.R89Q	17:7674220-7674220	13
4	COSM144310203	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	13
5	COSM142837352	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	13
6	COSM145017657	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	13
7	COSM105620276	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	13
8	COSM143156843	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.266G>A	p.R89Q	17:7674220-7674220	13
9	COSM122271559	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.347G>A	p.R116Q	17:7674220-7674220	13
10	COSM106053189	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	13
11	COSM143370869	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	13
12	COSM111758576	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	13
13	COSM112253622	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	13
14	COSM93183630	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	13
15	COSM144013367	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.710G>A	p.R237Q	17:7674220-7674220	13
16	COSM144651115	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.626G>A	p.R209Q	17:7674220-7674220	13
17	COSM87898351	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	13
18	COSM121875983	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.347G>A	p.R116Q	17:7674220-7674220	13
19	COSM122734176	TP53	skin,neck,carcinoma,squamous cell carcinoma	c.347G>A	p.R116Q	17:7674220-7674220	13
20	COSM133256111	TGFBR1	skin,neck,carcinoma,squamous cell carcinoma	c.1040C>T	p.S347F	9:99146601-99146601	13
21	COSM97906895	TGFBR1	skin,neck,carcinoma,squamous cell carcinoma	c.1016C>T	p.S339F	9:99146601-99146601	13
22	COSM135128838	TGFBR1	skin,neck,carcinoma,squamous cell carcinoma	c.1259C>T	p.S420F	9:99146601-99146601	13
23	COSM97922732	TGFBR1	skin,neck,carcinoma,squamous cell carcinoma	c.1247C>T	p.S416F	9:99146601-99146601	13
24	COSM84678061	SMO	skin,neck,carcinoma,squamous cell carcinoma	c.1103C>T	p.P368L	7:129206332-129206332	13
25	COSM98728167	RARA	skin,neck,carcinoma,squamous cell carcinoma	c.1384C>T	p.P462S	17:40356221-40356221	13
26	COSM107058787	RARA	skin,neck,carcinoma,squamous cell carcinoma	c.1093C>T	p.P365S	17:40356221-40356221	13
27	COSM98724263	RARA	skin,neck,carcinoma,squamous cell carcinoma	c.1432C>T	p.P478S	17:40356221-40356221	13
28	COSM86828717	RARA	skin,neck,carcinoma,squamous cell carcinoma	c.1384C>T	p.P462S	17:40356221-40356221	13
29	COSM98707797	RARA	skin,neck,carcinoma,squamous cell carcinoma	c.1369C>T	p.P457S	17:40356221-40356221	13
30	COSM94496058	RAD52	skin,neck,carcinoma,squamous cell carcinoma	c.439G>A	p.V147M	12:927173-927173	13
31	COSM133940534	RAD52	skin,neck,carcinoma,squamous cell carcinoma	c.439G>A	p.V147M	12:927173-927173	13
32	COSM107373333	RAD52	skin,neck,carcinoma,squamous cell carcinoma	c.439G>A	p.V147M	12:927173-927173	13
33	COSM130526023	RAD52	skin,neck,carcinoma,squamous cell carcinoma	c.439G>A	p.V147M	12:927173-927173	13
34	COSM96948694	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	13
35	COSM97161923	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	13
36	COSM96619514	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	13
37	COSM97161935	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	13
38	COSM144156675	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.473G>A	p.G158E	20:42352227-42352227	13
39	COSM96619533	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	13
40	COSM93273665	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	13
41	COSM96721565	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	13
42	COSM96835332	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	13
43	COSM142597931	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.454C>T	p.S152L	20:42352239-42352239	13
44	COSM144156682	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.461C>T	p.S154L	20:42352239-42352239	13
45	COSM97061657	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	13
46	COSM96835350	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	13
47	COSM96721578	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	13
48	COSM96948708	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	13
49	COSM93273656	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1619G>A	p.G540E	20:42352227-42352227	13
50	COSM97061670	PTPRT	skin,neck,carcinoma,squamous cell carcinoma	c.1607C>T	p.S536L	20:42352239-42352239	13

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

⁶ (show all 41)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	72234	12	7764270	8036678	Duplication	CLEC4C	Nasopharyngeal cancer
2	72235	12	7764270	8036678	Duplication	NANOG	Nasopharyngeal cancer
3	72236	12	7764270	8036678	Duplication	NANOGNB	Nasopharyngeal cancer
4	72237	12	7764270	8036678	Duplication	SLC2A14	Nasopharyngeal cancer
5	72238	12	7764270	8036678	Duplication	SLC2A3	Nasopharyngeal cancer
6	126614	19	19848080	20497256	Deletion	MIR1270	Nasopharyngeal cancer
7	126615	19	19848080	20497256	Deletion	MIR1270	Nasopharyngeal cancer
8	126616	19	19848080	20497256	Deletion	ZNF253	Nasopharyngeal cancer
9	126617	19	19848080	20497256	Deletion	ZNF486	Nasopharyngeal cancer
10	126618	19	19848080	20497256	Deletion	ZNF682	Nasopharyngeal cancer
11	126619	19	19848080	20497256	Deletion	ZNF826P	Nasopharyngeal cancer
12	126620	19	19848080	20497256	Deletion	ZNF90	Nasopharyngeal cancer
13	126621	19	19848080	20497256	Deletion	ZNF93	Nasopharyngeal cancer
14	132647	19	59423491	59445355	Deletion	LILRA6	Nasopharyngeal cancer
15	171484	3	168801287	168851758	Amplification	MECOM	Nasopharyngeal cancer
16	171493	3	168867391	169381563	Amplification	MECOM	Nasopharyngeal cancer
17	177937	3	65166887	65190844	Deletion		Nasopharyngeal cancer
18	197433	5	176843000	176857208	Deletion	PDLIM7	Nasopharyngeal cancer
19	205127	6	121025447	121050579	Deletion		Nasopharyngeal cancer
20	210827	6	31463047	31563588	Deletion	HCG26	Nasopharyngeal cancer
21	210828	6	31463047	31563588	Deletion	HCP5	Nasopharyngeal cancer
22	210829	6	31463047	31563588	Deletion	MICA	Nasopharyngeal cancer
23	210832	6	31463297	31559455	Deletion	HCG26	Nasopharyngeal cancer
24	210836	6	31463297	31559455	Deletion	HCP5	Nasopharyngeal cancer
25	210840	6	31463297	31559455	Deletion	MICA	Nasopharyngeal cancer
26	212636	6	4007991	32935606	Deletion	PSMB9	Nasopharyngeal cancer
27	220654	7	140736	180194	Duplication	CCDC146	Nasopharyngeal cancer
28	220655	7	140736	180194	Duplication		Nasopharyngeal cancer
29	220656	7	140736	180194	Duplication		Nasopharyngeal cancer
30	220657	7	140736	180194	Duplication	PMS2P11	Nasopharyngeal cancer
31	220658	7	140736	180194	Duplication	POMZP3	Nasopharyngeal cancer
32	222456	7	152200000	154700000	Duplication		Nasopharyngeal cancer
33	222457	7	152200000	154700000	Duplication		Nasopharyngeal cancer
34	222532	7	153118877	153284978	Duplication		Nasopharyngeal cancer
35	222533	7	153118877	153284978	Duplication		Nasopharyngeal cancer
36	224029	7	2721151	3758564	Duplication	CARD11	Nasopharyngeal cancer
37	224030	7	2721151	3758564	Duplication	GNA12	Nasopharyngeal cancer
38	227304	7	66680598	66860844	Deletion	AR	Nasopharyngeal cancer
39	229234	7	892539	3753994	Duplication		Nasopharyngeal cancer
40	236340	8	15447307	15475846	Deletion	TUSC3	Nasopharyngeal cancer
41	256863	9	9780222	9786577	Deletion		Nasopharyngeal cancer

Sources

Expression for Nasopharyngeal Carcinoma

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.

Sources

Pathways for Nasopharyngeal Carcinoma

Pathways related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	miRNAs involved in DNA damage response ⁷⁴	10.63	TP53 MIR29C MIR100
2	let-7 inhibition of ES cell reprogramming ⁷⁴ Show member pathways Metastatic brain tumor ⁷⁴	10.4	TP53 MIR29C